Clinical Performance Evaluation of HIV-1 RNA Kit

This study assessed the diagnostic specificity and sensitivity of a new in vitro diagnostic device, the HIV-1 RNA Quantitative Diagnostic Kit, by comparing it with a commercially available CE-marked RT-qPCR test. The evaluation used leftover human EDTA plasma specimens to ensure the accurate detection of HIV-1 RNA.

From the coordinator

In this study, the most important aspect was ensuring that the candidate diagnostic kit met the rigorous clinical and regulatory standards while providing accurate and reliable detection of HIV-1 RNA across a range of sample conditions.

PROJECT COORDINATOR Izabela
Chodara Director of Strategy and Operations

Challenges

Detecting the HIV-1 virus across a variety of clinical conditions and plasma samples with varying RNA concentrations.

Verifying the clinical accuracy of the HIV-1 RNA diagnostic kit in comparison to established CE-marked RT-qPCR tests.

Description of the study

The primary objective of this study was to evaluate the clinical performance of a new in vitro diagnostic device, the Human Immunodeficiency Virus Type 1 RNA Diagnostic Kit, designed for the quantitative detection of HIV-1 RNA. This kit utilizes PCR-Fluorescence probing technology, making it suitable for detecting HIV-1 RNA through fluorescent signal changes. By comparing the results from this new diagnostic kit with a commercially available CE-marked RT-qPCR test, the study aimed to assess its diagnostic specificity and sensitivity.

Ultimately, the study demonstrated that the HIV-1 RNA Diagnostic Kit generates results comparable to the CE-marked RT-qPCR test, meeting high standards for both diagnostic sensitivity and specificity. This outcome supports the kit’s use as a reliable tool for detecting and quantifying HIV-1 RNA in clinical practice.

Results

The study demonstrated that the HIV-1 RNA Diagnostic Kit showed comparable diagnostic sensitivity and specificity to the CE-marked RT-qPCR test.

The kit reliably detected HIV-1 RNA Diagnostic Kit in EDTA plasma specimens, providing accurate quantitative results that met European standards for in vitro diagnostic devices.

Key findings

Izabela Chodara

Project Manager

I will help your company in developing:

iVD

R&D

performance studies

clinical investigations

biobanking

First Name

Last Name

Country

Company Name

Email Address

Phone

Other case studies

Clinical Evaluation of Class III Vascular Implants – Transition from MDD to MDR

The authority responsible for regulating medical devices in the United Kingdom is the MHRA. If the manufacturer is based outside the UK, they must appoint a UK Responsible Person (UKRP).

Check

Efficacy and safety evaluation in clinical trial of dermal filler

This study assesses the efficacy and safety of the dermal filler for treating medium facial lines, including nasolabial folds and marionette lines, over a 24-month follow-up period. It aims to generate comprehensive clinical data through post-market clinical follow-up (PMCF).

Check

Clinical investigation on a novel resorbable medical barrier

This completed clinical investigation evaluated the safety, resorption profile, and clinical performance of a resorbable medical barrier intended to support natural tissue regeneration. The study was conducted in alignment with the requirements of the EU Medical Device Regulation (MDR) and ISO 14155:2020, with Pure Clinical serving as the CRO responsible for full project oversight.

Check